|
Molecular Partners Ag (NASDAQ: MOLN) |
|
Molecular Partners Ag
MOLN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Molecular Partners Ag's sales fell
by -96.29 % in the fourth quarter of 2023 from the same quarter a year ago.
Ranking at No. 5
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -1.86 %
Molecular Partners Ag faced net loss in contrast to the net income a year ago in fourth quarter of 2023
• More on MOLN's Growth
|
|
Molecular Partners Ag realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.36 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 17.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.39.
• More on MOLN's Valuation
|
|
|
|
|
Molecular Partners Ag realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.36 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 17.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.39.
Molecular Partners Ag Price to Book Ratio is at 0.68 lower than Industry Avg. of 2008.64. and higher than S&P 500 Avg. of 0.01
• More on MOLN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com